NHLBI TOPMed - NHGRI CCDG: AF Biobank LMU in the context of the MED Biobank LMU

The Atrial Fibrillation Biobank Ludwig Maximilian University (AFLMU) Study contributes to the spectrum of disease by adding carefully characterized patients with atrial fibrillation. Atrial fibrillation, one of the most common human arrhythmias confers major morbidity, mortality and health care cost, and has been demonstrated to be caused and influenced by genetic and -omics factors. Particularly, AFLMU enrolled patients with an early onset of atrial fibrillation to increase the genetic burden on disease pathophysiology. All patients were recruited applying standardized protocols to maintain homogeneity in data and DNA quality.]]>
TOPMed Whole Genome Sequencing Methods: Freeze 9TOPMed Whole Genome Sequencing Methods: Freeze 10Inclusion criteria encompassed diagnosis of atrial fibrillation with a disease onset at ≤65years, or presentation for catheter ablation of atrial fibrillation.]]>
AFLMU was initiated originally in 2001 (then MAGiC-AF Project) and has consecutively been continuing patient enrollment since.]]>